For many emerging biotechs, CMC is the part of development that feels furthest from the science — yet it’s often the part that determines whether a programme moves forward smoothly or gets stuck in avoidable delays. Regulators don’t treat CMC as a formality, and neither should sponsors. The quality, consistency, and scalability of the product are inseparable from its safety and efficacy, even in the earliest phases.
A strong CMC strategy doesn’t need to be complicated, but it does need to be deliberate. Here are five steps that help early phase teams avoid the pitfalls that most often derail development — and build a foundation that supports a clean, confident path to first in human.
Start with the end in mind — even at the beginning
Early phase sponsors often focus on “getting material made” rather than building a manufacturing approach that can scale. But regulators expect a clear understanding of:
-
critical quality attributes
-
the rationale behind process steps
-
how variability will be controlled
-
how analytical methods and the control strategy will mature
-
how the process will evolve as the programme matures
Thinking ahead doesn’t mean locking in a commercial ready process on day one. It means understanding what will need to be demonstrated later — and designing early work so it can support that journey, including early definition of reference standards and phase‑appropriate assay robustness.
Choose CDMO partners with care — and with eyes open
CDMO selection is one of the most consequential decisions a biotech makes. Cost matters, but it’s rarely the most expensive part of the equation. The real risks lie in:
-
inconsistent quality systems
-
limited regulatory experience
-
weak process control or analytical control
-
unreliable timelines
-
poor communication or documentation
-
gaps in raw‑material or supply‑chain management
A CDMO that looks inexpensive on paper can become costly if it requires constant oversight or produces material that doesn’t meet regulatory expectations. Early due diligence, including QA audits and clear alignment on responsibilities, saves time and money later.
Understand scale up and scale down before they become bottlenecks
Biologics and advanced therapies don’t always scale linearly. Fermenter geometry, oxygen transfer, agitation, and shear forces can all influence product quality. A process that works beautifully at 2 L may behave very differently at 200 L.
-
Sponsors should work with partners who can:
-
model scale up and scale down accurately
-
identify parameters that truly matter
-
design experiments that reveal process sensitivities
-
plan comparability assessments early
-
ensure analytical methods can detect scale‑related differences
This foresight prevents the “unexpected variability” that often appears when programmes transition from early batches to clinical supply.
Build risk management into the process, not around it
Every manufacturing process carries risk — contamination, variability, equipment failure, raw material inconsistency or assay drift. The strongest CMC strategies identify these risks early and build controls directly into the process.
This includes:
-
defining critical process parameters
-
establishing in process controls
-
validating analytical methods
-
ensuring traceability across the supply chain
-
implementing early data‑integrity and documentation practices
Risk management isn’t a regulatory box tick. It’s the mechanism that keeps a programme on track when timelines are tight and material is precious.
Plan for regulatory scrutiny from the start
Even in early phase submissions, regulators expect clarity on:
-
how the product is made
-
why the process is appropriate
-
how quality is assured
-
how changes will be managed
-
how analytical methods, specifications, and control strategy will evolve
-
how changes will be assessed and managed through comparability
A well prepared CMC package demonstrates control, foresight, and scientific understanding. A weak one invites questions, delays, and additional work.
Sponsors who treat CMC as a strategic pillar — not a technical afterthought — are the ones who move through IND/CTA review with fewer surprises.
Where an early phase specialist ecosystem strengthens CMC decisions
CMC doesn’t exist in isolation. It influences — and is influenced by — non clinical design, clinical pharmacology, regulatory strategy, analytical development, and operational planning. When these functions operate separately, important connections are missed: a manufacturing change that affects PK, an assay that doesn’t align with clinical endpoints, a packaging choice that affects stability a process adjustment that triggers regulatory questions.
An early phase specialist ecosystem brings these threads together. CMC experts work alongside clinical, regulatory, supply‑chain, and analytical teams who understand how each decision will play out downstream. That integration gives sponsors a clearer view of what matters, what can wait, and what needs to be addressed now.
The Bottom Line
A strong CMC strategy is one of the most reliable ways for early phase biotechs to reduce risk, protect timelines, and build credibility with regulators and investors. It’s not about over engineering the process — it’s about making thoughtful decisions early, supported by people who understand how those decisions shape the path ahead.
When CMC is developed within a connected early phase ecosystem, sponsors gain the confidence that every part of the programme is aligned — scientifically, operationally, and strategically — from the first batch to first in human.
